 Based on a thorough reassessment Sesen Bio Inc NASDAQ: SESN has decided to voluntarily pause further development in the U.S. of its lead asset, Vicineum, for non-muscle invasive bladder cancer NMIBC. The decision was based on a reassessment of the incremental development. 